299 results on '"Hulstaert, Frank"'
Search Results
2. Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer
3. Belgian observational survival data (incidence years 2004–2017) and expenditure for innovative oncology drugs in twelve cancer indications
4. Survival of patients with unfavorable prognosis cutaneous melanoma with increased use of immunotherapy agents: a population‐based study in Belgium.
5. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial
6. Effectiveness of nirmatrelvir‐ritonavir on severe outcomes of COVID‐19 in the era of vaccination and Omicron: An updated meta‐analysis
7. Budgeting of non-commercial clinical trials: development of a budget tool by a public funding agency
8. Replacing RCTs with real world data for regulatory decision making: a self-fulfilling prophecy?
9. Survival in stage IV ovarian cancer with increased use of debulking surgery and bevacizumab
10. Proton Therapy in Children: A Systematic Review of Clinical Effectiveness in 15 Pediatric Cancers
11. Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?
12. Transcatheter aortic valve implantation (TAVI): risky and costly
13. Market Introduction of Innovative High Risk Medical Devices : Towards a Recast of the Directive Concerning Medical Devices
14. Contingent non-invasive prenatal testing: an opportunity to improve non-genetic aspects of fetal aneuploidy screening
15. The importance of test accuracy in economic evaluations of companion diagnostics
16. Stereotactic Body Radiotherapy for Lung Cancer: How Much Does it Really Cost?
17. Evidence gaps for drugs and medical devices at market entry in Europe and potential solutions
18. Mise sur le marché des médicaments et des dispositifs médicaux en Europe : manque de données probantes et solutions possibles : Synthése
19. Markttoegang in Europa voor geneesmiddelen en medische hulpmiddelen: gebrek aan bewijs en mogelijke oplossingen : Synthése
20. Evidence gaps for drugs and medical devices at market entry in Europe and potential solutions : Synthese
21. Critical Assessment of Belgian Reimbursement Dossiers of Orphan Drugs
22. Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies
23. Infectious diseases epidemiology, quantitative methodology, and clinical research in the midst of the COVID-19 pandemic: Perspective from a European country
24. Comparative effectiveness research and measuring the level of pharmaceutical innovation in the EU
25. Stimulating pharmaceutical innovation in the EU
26. Closing the cycle of innovation in healthcare in Europe
27. How many CIN2+ lesions can be avoided through HPV 16/18 vaccination?
28. MOESM1 of Budgeting of non-commercial clinical trials: development of a budget tool by a public funding agency
29. Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimerʼs disease and dementia with Lewy bodies
30. Immunogenicity and Tolerability of Intradermal Administration of an HCV E1-Based Vaccine Candidate in Healthy Volunteers and Patients with Resolved or Ongoing Chronic HCV Infection
31. Virologic therapy response significantly correlates with the number of active drugs as evaluated using a LiPA HIV-1 resistance scoring system
32. A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers
33. Kinetics of disappearance of resistance mutations and reappearance of wild-type during structured treatment interruptions
34. Tropisetron for Treating Established Postoperative Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Study
35. Expression of activation antigens, HLA-DR and CD38, on CD8 lymphocytes during HIV-1 infection
36. Expanded carrier screening in a reproductive context. Towards a responsible implementation in the healthcare system
37. Introduction of high-risk medical devices: national measures that can be taken under the current European legislation to put the patient interest central
38. Publicly funded practice-oriented clinical trials: of importance for healthcare payers
39. Improved Discrimination of AD Patients Using [[beta]-Amyloid.sub.(1-42)] and Tau Levels in CSF
40. The non-invasive prenatal test (NIPT) for trisomy 21 : health economic aspects - Synthesis
41. De niet-invasieve prenatale test (NIPT) voor trisomie 21 : Gezondheidseconomische aspecten - Synthese
42. Test prénatal non invasif (NIPT) pour la trisomie 21 : aspects économiques – Synthèse
43. The importance of test accuracy in economic evaluations of companion diagnostics
44. Innovatieve radiotherapie-technieken : een multicenter time-driven activity-based costing studie - synthese
45. Innovative radiotherapy techniques : a multicentre time-driven activity-based costing study - Synthesis
46. Should chronic hepatitis B be treated as early as possible?
47. Innovative radiotherapy techniques : a multicentre time-driven activity-based costing study
48. Techniques innovantes en radiothérapie : une ét ude multicentrique d’évaluation du cout via la méthode ABC pilotée par le temps – synthèse
49. Pre-market clinical evaluations of innovative high-risk medical devices in Europe
50. Direct-to-consumer genetic testing services : PUBLICATION OF THE SUPERIOR HEALTH COUNCIL No. 8714
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.